INTRODUCTION
The alkyl hydroperoxidase (AhpCF) system of Gram-negative bacteria such as E. coli and Salmonella typhimurium provides an important means of defense against the presence of peroxides in the environment and against their generation within the cell. The two components of this peroxidase system, AhpC (a peroxiredoxin) and AhpF (a flavoprotein disulfide reductase), are induced by as much as 20-fold under conditions of oxidative stress (Christman et al., 1985) , although AhpC is in high abundance even in the absence of induction (Wood et al., 2002) . AhpC, utilizing its C46, directly attacks a hydroperoxide, leading to formation of a sulfenic acid derivative (R-SOH) of the cysteine and reduction of the peroxide (Figure 1 ). The C46 sulfenic acid then reacts with a second cysteine in AhpC, C165, generating water and a disulfide bond between the two cysteines. This disulfide bond in AhpC is subsequently reduced by a pair of cysteines in the thioredoxin-like domain of AhpF, regenerating the active peroxidase. The now oxidized thioredoxin-like domain of AhpF is reduced by a second dithiol center within the thioredoxin reductase-like module of AhpF. The resulting disulfide bond in this part of the protein is reduced by electrons transferred from an AhpF-bound flavin moiety. The final step in this electron cascade is carried out by NADH, which reduces the oxidized flavin (Poole, 2005) .
The second step in this process, the formation of the C46-C165 disulfide bond, occurs not between cysteine residues in a monomeric form of AhpC but, rather, between C46 in one monomer and C165 in a second monomer found in a dimeric form of AhpC. The oxidized form of AhpC is dimeric in dilute solutions and decameric only at high concentrations, whereas the reduced form is exclusively decameric (Wood et al., 2002) .
We have described a remarkable mutant form of AhpC in which the addition of a single amino acid to the protein results in an AhpC that is devoid of peroxidase activity but is now able to channel electrons into the glutathione/glutaredoxin pathway (Ritz et al., 2001 ). This mutation, ahpC*, was obtained at high frequencies as a suppressor of a strain that was unable to grow in the absence of an exogenous reductant because it carried gene mutations knocking out the source of electrons for the two cytoplasmic disulfide reducing pathways, thioredoxin reductase and glutathione reductase (trxB gor). The failure to grow of the nonsuppressed strain is due to the absence of electrons passing through these pathways that are required for the reduction of such essential substrates as ribonucleotide reductase (RNR) (Ortenberg et al., 2004) . RNR itself uses redox-active cysteines to reduce ribonucleotides, thus producing a disulfide-bonded form of the enzyme during its reaction and, therefore, requiring regeneration by reduction. Sequencing of the ahpC* mutant gene showed an expansion of a four triplet repeat sequence in the wild-type sequence to a five triplet repeat in the mutant form, resulting in the addition of a phenylalanine. The additional amino acid is inserted close to C46, nine residues to its N-terminal side.
Because this mutation ablates the peroxidase activity, ahpC* mutants could not be stably maintained in a catalase-deficient mutant; revertants to wild-type ahpC accumulated rapidly in this trxB gor katG background (Ritz et al., 2001) .
Genetic studies with the strain trxB gor ahpC* showed that the suppressing activity of ahpC* still required AhpF and that it acted through the glutathione/glutaredoxin pathway (Ritz et al., 2001) ; transduction of null mutations that knocked out either glutaredoxin 1 (grxA) or g-glutamyl-cysteine synthetase (gshA) (eliminating glutathione biosynthesis) prevented suppression, whereas mutations eliminating the thioredoxins had no effect on suppression (see Figure S1 , available online, for a diagram of electron flow in AhpC and AhpC* expressing bacteria). Although these results suggested that electrons were being transferred from AhpC* to oxidized glutathione and/or glutaredoxins, in vitro studies with the purified protein indicated no increased activity toward these substrates.
In this paper, we report studies that pursue several aspects of these surprising findings. First, we have shown that AhpC* does not employ the same mechanism as AhpC to transfer electrons to substrates, as it uses the resolving cysteine C165 rather than the peroxidatic C46 for its activity. Second, we have identified amino acid changes in the protein other than the amino acid insertion found in AhpC* that can cause a similar functional transformation of AhpC. Third, we have sought to identify the likely substrate for AhpC* by in vitro approaches and have identified an enhanced glutaredoxin deglutathionylating activity for mutant AhpC proteins that act as suppressors of trxB gor. These results have yielded some new surprises and have allowed us to identify a key substrate for AhpC* and other mutant proteins that suppress trxB gor growth defects and contribute to redox homeostasis in E. coli.
RESULTS
C165, but Not C46, Is Necessary for the Disulfide Reductase Activity of AhpC* In wild-type AhpC, C46 is the cysteine that attacks hydrogen peroxide and becomes oxidized to a sulfenic acid derivative, whereas C165 resolves the C46 sulfenic acid generating a water molecule and a C46-C165 intersubunit disulfide bond. We asked whether the same steps, starting with the attack of C46 on a substrate, might be involved in the action of AhpC* by determining whether both cysteines were required for its activity. We constructed plasmids carrying various combinations of mutations in ahpC and introduced them into a trxB gor strain carrying a wild-type ahpCF operon and one that was deleted for the ahpCF operon (Table 1) . When a mutation changing C165 to serine was introduced into AhpC*, the protein became completely inactive as a suppressor of the trxB gor strain, a somewhat expected result given the role of C165 in the peroxidase activity and in interactions of AhpF with AhpC (Ellis and Poole, 1997; Jö nsson et al., 2007) . However, a C46S change in AhpC* did not interfere with the suppressing ability of this protein, even though that amino acid is the redox-active cysteine that interacts Catalysis of peroxide reduction by AhpC proceeds through the intermediate formation of an oxidized form of the peroxidatic cysteine (C46), the sulfenic acid (R-SOH). In the next step, an intersubunit disulfide bond is formed between the peroxidatic and resolving (C165) cysteinyl residues, which are located on adjacent subunits within a dimer. To complete the catalytic cycle of AhpC, electrons from NADH are channeled through AhpF to reduce the disulfide bond at the active site of AhpC, reactivating it for another cycle of peroxide reduction. 
Strains grown on plates containing 0.2 % arabinose (to allow expression of the araBAD-controlled trxB gene) and the antibiotics to maintain the plasmids were restreaked onto plates containing 0.2 % glucose and 100 mM IPTG. Growth was scored after 24 hr at 37 C as the ability to form colonies. b The background strains used were JL10 (trxB gor) and DR456 (trxB gor ahpCF::Km), a JL10-derived strain that was obtained by introducing the ahpCF::Km (deletion of codons 62-187 of ahpC and codons 1-406 of ahpF) deletion into JL10. c Note the lack of suppressor activity by the C46S,C165S mutant of AhpC in the wild-type ahpCF background (in contrast to the C46S and C46S,C165S mutants of AhpC*, discussed in the text). This may be explained by the very weak suppressor activity observed for the C46S mutant that, when further lessened in the formation of heterooligomers, is likely insufficient for suppression of the growth defect (see plates in Figure S2 ).
with peroxides in the wild-type AhpC. This result indicates a dramatic change in the cysteine involved in the first step in substrate reactions of AhpC from C46 in the wild-type protein to C165 in the AhpC* protein.
Further analysis of the AhpC suppressor mutations yielded other unexpected results. First, an otherwise wild-type ahpCF operon expressing the C46S version of AhpC itself conferred suppression of the growth defect of the trxB gor strain, albeit weakly so. Second, both the ahpC* and ahpC (C46S) alleles, which conferred suppression of the growth defect, did so even in a strain carrying a wild-type ahpCF operon. Third, a plasmid expressing an AhpC* with both of its cysteines converted to serines, which could not act as a suppressor in the background deleted for ahpCF, did so in a background where the wild-type ahpCF operon was present (Table 1) . These latter results suggest that a mutant AhpC protein, AhpC* lacking any cysteine residue, present in heterooligomeric AhpC can transform that oligomer so that it functions as a suppressor of the trxB gor growth defect (see Discussion).
Other Single Amino Acid Replacements in AhpC Confer a Suppressor Phenotype without Eliminating Peroxidase Activity To further explore the nature of the changes in AhpC that allow it to channel electrons into the glutathione pathway, we sought other kinds of mutations that would confer the suppressing phenotype on the protein. Except for the C46S mutation described above, the ahpC suppressors reported previously were all due to the same mutation-the triplet repeat expansion. Such triplet repeat expansions occur at a much higher frequency than any other point mutations that might have also conferred a suppressor phenotype. To circumvent this limitation and determine whether other mutations in the ahpC gene could confer a suppressor phenotype, we used two strategies. In the first, we mutagenized a plasmid carrying the ahpCF operon and selected for suppressors in the DR456 background, which is deleted for trxB gor and ahpCF and carries pBADtrxB. This selection yielded seven different mutants each carrying single amino acid changes, S159P, P161S, A167T, P166S, C46Y, R119C, and G141S. The C46Y change represented the second instance of a mutation altering C46 resulting in a suppressor phenotype (see C46S in previous section). Along with C46Y, we also constructed by oligonucleotide mutagenesis a mutation that generated a C46F change. These two alterations, along with the other new mutants obtained in the screen, restored to the trxB gor strain a growth phenotype similar to the ahpC* mutation, in contrast to the weakly suppressing C46S change. In the studies that follow, we have chosen to analyze in detail only a subset of these mutants and their protein products.
A second approach to obtaining suppressors other than ahpC* in the chromosomal ahpC gene was based on the knowledge that the ahpC* mutation eliminated the normal peroxidase activity of the protein and could not be stably maintained in a katG mutant. With this approach, we reasoned that selection for suppressors in this gor trxB katG strain was unlikely to yield ahpC* mutations and instead would yield only those suppressors that still retained at least some of the AhpC peroxidase activity. We performed the selection for growth in this strain and found one mutant that contained the amino acid change P166L in AhpC. When the plasmids carrying this and the above suppressor mutations (ahpC*, P166S, P166L, S159P, P161S, C46Y, and A167T) were introduced into a trxB gor strain that carried a wildtype ahpCF operon, they behaved as dominant mutations still conferring suppression.
To determine whether the mutants obtained by these two approaches did still retain peroxidase activity, we used two methods for assessing the effects on peroxidase activity: one which measured peroxide-dependent transcriptional activity of OxyR in vivo with a trxC promoter fused with lacZ (Christman et al., 1989; Ritz et al., 2000) and a second that relied on an in vitro peroxidase assay (Parsonage et al., 2005) (Table 2 ). For the in vivo assays, the plasmids carrying the four mutations S159P, P161S, P166L, and A167T were transformed into a strain lacking ahpCF and katG and carrying P trxC -lacZ. All four plasmids expressed AhpC proteins that showed at least some peroxidase activity as assessed by the expression of P trxC -lacZ. One of them, P161S, expressed peroxidase levels indistinguishable from those of wild-type by this measure, but the remaining three must have reduced levels of peroxidase activity as indicated by higher levels of b-galactosidase activity. None of them expressed as high a OxyR-dependent b-galactosidase expression of the chromosomal trxC'-'lacZ fusion in response to various ahpC-containing plasmids, wild-type (pJL34), P161S (pDR1056), A167T (pDR1053), S159P (pDR1052), and P166L (pAG4), was measured (given in Miller units) (Miller, 1972) . b Units of b-galactosidase activity were normalized to 100% peroxidase activity for wild-type ahpC-expressing plasmid versus this strain, HP27, containing only the plasmid vector (836 units; see Experimental Procedures). The numbers presented in this column do not represent actual peroxidase activity but should at least reflect the relative order of amounts of activity. The HP27 strain lacks ahpCF and katG. AhpC* exhibits no peroxidase activity by either assay. c k cat and K m data from Parsonage et al. (2005) .
levels of P trxC -lacZ as the AhpC* and C46Y strains (data not shown for the latter protein). As reported earlier, AhpC* completely lacks the AhpC peroxidase activity (Ritz et al., 2001) . In order to directly measure peroxidase activity, we purified several of the mutant AhpC proteins and carried out bisubstrate kinetic assays, which evaluate true k cat values as well as the K m for both oxidizing and reducing substrates. Using such an assay, wild-type AhpC was previously demonstrated to exhibit a very high catalytic efficiency ($4 3 10 7 M À1 s
À1
) and low K m (1.4 mM) toward hydrogen peroxide (Parsonage et al., 2005) . As indicated by the reporter assays above, all four suppressor mutant proteins purified, S159P, P161S, P166L, and A167T, exhibited peroxidase activities, three of them considerably lower than that of wild-type AhpC (Table 2 ). For all four mutants, the data give exactly the same order of peroxidase activities for the purified proteins as the corresponding in vivo data from the P trxC -lacZ reporter system. OxyR activation in the trxC promoter-reporter construct is apparently giving a ''readout'' of activity in terms of higher steady-state peroxide levels that correlates with the lower k cat /K m values of the mutants (Table 2) , even though the in vivo assay could in theory be somewhat complicated by the redox regulation of OxyR by Grx1 and the regulation of Grx1 expression by OxyR. Still, the fact that expression of AhpC*, with no peroxidase activity but full disulfide reductase activity, does not affect the high level of OxyR activation (compared with vector only), along with the congruence between the two assay approaches, suggests that the OxyR activation assay is primarily a readout of peroxidase activity.
Like ahpC*, the New Suppressor Mutations Depend on the Glutathione/Glutaredoxin Pathway and Not the Thioredoxin Pathway We have asked whether, like the AhpC* suppression, the new suppressor mutations we have obtained are channeling electrons into the glutathione/glutaredoxin pathway rather than the thioredoxin pathway. Deletions that remove the genes for thioredoxin 1 (trxA), glutaredoxin 1 (grxA), or g-glutamyl-cysteine synthetase (gshA) were separately introduced into strains carrying the new ahpC point mutations on a plasmid. We found that, like AhpC*, the mutant proteins C46S, C46F, C46Y, P166S, S159P, P161S, and A167T all required for their suppressing activity the presence of the glutathione/glutaredoxin pathway, but not the thioredoxin pathway (Table 3) .
Further evidence that these ahpC suppressor mutations are causing electrons to be channeled into the glutathione pathway comes from comparisons of the reduced and oxidized glutathione (GSH and GSSG, respectively) contents of wild-type and trxB gor mutants either expressing or not ahpC*F . These measurements showed a higher level of GSH in the strain containing AhpC* than the level of GSH in the trxB gor background (Figure 2 ) (Masip et al., 2006) . This result suggests that AhpC* either directly or indirectly contributes to glutathione reduction in vivo. We also found increased amounts of total glutathione in the trxB gor ahpC* strain. In assessing bacteria expressing several of the other suppressor mutants for glutathione content and redox state, as well, we found that total glutathione levels were mostly not different compared to the parental wild-type strain DHB4 but that the GSH/GSSG ratio was again extremely high.
For comparison, expression of wild-type AhpC in this background led to levels of total glutathione similar to those with expression of AhpC*, but $40% of that glutathione was oxidized (see Figure S3 ).
In Vitro Properties of the AhpC Mutant Proteins
We have purified the AhpC* protein in preparation for X-ray crystallographic studies and in order to study its substrate specificity. One interesting structural attribute of wild-type AhpC is that, when reduced, it forms stable decamers (as pentamers of homodimers, [a 2 ] 5 ) that tend to dissociate into dimers when the protein is oxidized (Wood et al., 2002) . Unlike the wild-type protein, AhpC* was present only as dimers irrespective of its redox state based on analytical ultracentrifugation studies (see the Supplemental Data for details). This result suggests a significant conformational change in the protein compared to the wild-type. Therefore, we also assessed the oligomeric state of several of the AhpC point mutants, S159P, A167T, P166L, P161S, and C46Y. Whereas reduced wild-type AhpC is a decamer at all concentrations studied and AhpC* is a dimer at all concentrations independent of redox state, four of the five reduced mutant proteins showed some degree of decamer dissociation once their concentration dropped below 40 mM ( Figure S4) . Interestingly, the tendency of these mutants to dissociate at 10 mM follows the same order as the increasing K m measured for those with peroxidase activity; P161S maintains a stable decamer like wild-type AhpC and has a very low K m for H 2 O 2 , whereas S159P shows the greatest tendency to dissociate at this concentration and has the highest K m for H 2 O 2 (Table 2) . (Table S1 ) were transformed into the various strains and grown in the presence of DTT. These strains were then grown on NZ-amine plates containing 50-150 mM IPTG at 37 C. Pluses/minuses correspond to ability to form colonies and colony size: À, no colony formation, no growth; +, small colonies; and ++, growth similar to AhpC*. ND, not determined. b Although the DtrxA mutation causes a very slight but observable growth defect in all strains, this defect is more pronounced with C46S and P161S. C46S is the weakest suppressor, and P161S may also be weaker than the rest (see its high peroxidase activity), so both may be more sensitive to the general effect of the trxA mutation. Pictures of the colonies on these plates are presented in Figure S2 .
An In Vitro Substrate for AhpC* The in vivo ahpC* suppressor phenotype depends on the presence of the gshA and grxA genes, indicating that glutathione and glutaredoxin 1 are necessary for the AhpC*-dependent restoration of cytoplasmic-reductive capacity and, thus, that electrons are transferred into this pathway. Additionally, glutathione is predominantly reduced in trxB gor ahpC*, indicating that expression of AhpC* results in the reduction of glutathione. We first asked whether the purified AhpC* protein could directly reduce oxidized glutathione in vitro. Although the protein did show such activity, it was low and only marginally greater than that seen with the wild-type protein (about 3-to 4-fold greater activity for AhpC* than for AhpC, Figure 3A , second and third bars). This amount of activity is unlikely to be sufficient to support growth (see Discussion). Similar results were obtained for reduction of 5,5 0 -dithiobis(2-nitrobenzoic acid) (DTNB), a disulfide-containing small molecule that can be used as a model to assess a generic disulfide reductase activity (Ritz et al., 2001) . It seemed that, at this point, three main possibilities consistent with the in vivo results remained: AhpC* might directly reduce (1) oxidized glutaredoxin 1, (2) a mixed disulfide between glutathione and glutaredoxin 1, or (3) one or more glutathionylated proteins that accumulate during disulfide stress. Although glutaredoxins are normally reduced by reduced glutathione, reduced glutaredoxins are reportedly also able to reduce oxidized glutathione given their similar redox potentials (Equation 1) (Porras et al., 2002) . With glutathionylated proteins, including glutathionylated glutaredoxins, reduced glutathione can be released if AhpC* can reduce the mixed disulfide bond between glutathione and protein (Equation 2). We chose glutathionylated Grx1 as a potential substrate of AhpC* because Grx1 is required for the suppressor activity in vivo. Specifically, we Cells were grown to exponential phase (A 600 = $0.5) in LB medium. For the expression of AhpC*F (+), MJF306 (trxB gor ahpCF/pLacYC-ahpC*F) was grown with both chloramphenicol (25 mg/ml) and IPTG (0.1 mM). These cells were collected by centrifugation and used for glutathione measurement as described in the Experimental Procedures. To monitor the glutathione status in MJF306 in the absence of AhpC*F expression (À), MJF306 cells were grown in LB medium plus glucose (0.2%) and DTT (2 mM) to exponential phase (A 600 = $0.5), then pelleted and resuspended in LB medium plus glucose without DTT. After 1 hr incubation at 37 C, cells were used for glutathione measurement; black bars represent reduced glutathione, and gray bars represent oxidized glutathione. The oxidized glutathione content is shown as equivalents of reduced glutathione, i.e., one oxidized glutathione is shown as two reduced glutathione equivalents. The data shown are the means ± standard deviation of triplicate determinations. For all experiments, reaction mixtures included 1 mM GSSG, 0.5 mM of AhpF, and 0.8 mM NADH; incubations were carried out at 22 C. Proteins were precipitated by addition of 5% metaphosphoric acid, and the supernatants were assayed for GSH by using a DTNB assay. AhpC or mutants, where present, were at 5 mM, and Grx1 or Grx1 C14S, where present, was at 10 mM. In (A), the indicated mixtures were incubated for 30 min prior to GSH assay. In (B) and (C), all reactions included Grx1 C14S and one of the AhpC proteins as described. In (B), four point mutants that complement trxB gor mutations in E. coli were assayed for comparison with AhpC and AhpC* deglutathionylating activity; curves shown are for AhpC* (,), S159P (D), P166L (-), A167T (:), P161S (C), and wild-type AhpC (B). In (C), AhpC* mutants involving deletion of the peroxidatic (C46S, C) or resolving cysteine (C165S, -) residues were compared with deglutathionylating activities of AhpC (B) and AhpC* (,). All data in these panels show the means ± standard deviation of triplicate determinations.
used a Grx1 C14S mutant that lacks the second (resolving) cysteine and therefore could be isolated as a stably glutathionylated protein.
(1)
Reductive activities of AhpC* and wild-type AhpC toward glutathionylated Grx1 C14S were monitored by measuring GSH formation in the reaction mixture. As shown in Figure 3A and mentioned above, only a small amount of glutathione was reduced in the reaction mixture containing only NADH, AhpF, GSSG, and either AhpC* or AhpC. However, the addition of the Grx1 C14S mutant strongly stimulated GSH formation ( Figure 3A , right side). Under these in vitro conditions, generation of reduced glutathione by AhpC* in the presence of the Grx1 C14S mutant protein was 6-fold faster than that by AhpC and the Grx mutant protein and 27-fold faster than that of AhpC* without the Grx1 C14S mutant protein. This result indicates that AhpC* can reduce a mixed disulfide between the remaining cysteine of Grx1, C11, and glutathione. To confirm the deglutathionylation of Grx1 C14S by AhpC*, glutathionylated Grx1 C14S (Grx1 C14S S-SG) was prepared and used as a substrate for AhpC*/AhpF or AhpC/AhpF systems in the presence of NADH. Treatment of Grx1 C14S S-SG with the AhpC*/AhpF system resulted in reduction of the mixed disulfide bond between Grx1 C14S and glutathione (Equation 2) as confirmed by MALDI-TOF mass spectrometry; parallel treatment with wild-type AhpC and AhpF also resulted in deglutathionylation of Grx1 C14S S-SG, but at a rate that was $6-fold slower than for AhpC* (data not shown). The addition of wild-type Grx1, in place of Grx1 C14S, to these reaction mixtures only slightly stimulated reduced glutathione formation ( Figure 3A ), indicating that (1), without the C14S mutant protein, little accumulation of glutathionylated glutaredoxin takes place under these in vitro conditions and (2) neither AhpC* nor AhpC can reduce oxidized Grx1 at an appreciable rate.
We also used the monothiol glutaredoxin Grx4 (Fernandes et al., 2005) as a substrate for AhpC*. Both the reduced glutathione formation assay and MALDI-TOF mass spectrometry analysis showed that AhpC* has better reductase activity toward glutathionylated-Grx4 (Grx4 S-SG) than does AhpC (data not shown). However, the rate of glutathione release from Grx4 S-SG was much slower than that from Grx1 C14S S-SG (by about 40-fold). Using the Grx1 C14S-dependent glutathione reductase activity as an in vitro Grx-S-SG reductase assay for the activity of AhpC* that appears to correlate with in vivo function, four of the new point mutants with both suppressor and peroxidase activity were tested and compared with the levels of activity conferred by either AhpC or AhpC* proteins. In fact, all four mutants exhibited similar (P161S, A167T, and P166L) or higher (S159P) activity than AhpC*; all these AhpC mutant proteins, in turn, exhibit higher activity than that of wild-type AhpC itself ( Figure 3B ). When the requirement for either the peroxidatic (C46) or resolving (C165) cysteine for activity was assessed with this assay, it was again clear that C165, but not C46, is required for this activity of AhpC* ( Figure 3C ). Thus, the results from the new in vitro assay correlate very well with the in vivo functional assessment of the suppression of the trxB gor growth defect.
DISCUSSION
In this paper, we examine the remarkable changes in substrate specificity and reaction mechanism of a protein that result from single amino acid changes. In the most extreme case, the addition of a single amino acid to the AhpC protein converts it from a peroxidase to a protein (AhpC*) that can reduce mixed disulfides between glutathione and glutaredoxins. In the newer mutants reported here, single amino acid substitutions generate AhpC derivatives that gain the Grx-S-SG reductase activity but retain some peroxidase activity. Surprisingly, in the case of AhpC*, the conversion of the peroxidase to a Grx-S-SG reductase changes the protein from one that uses the peroxidatic C46 to attack substrates to one that uses C165 for restoring electron flow into the glutathione/glutaredoxin pathway. Although both cysteines are required for efficient peroxidase functioning of AhpC (Ellis and Poole, 1997), C46 is not required for the Grx-S-SG reductase activity of AhpC* ( Figure 3C ).
Genetic results with ahpC* reported previously (Ritz et al., 2001) and results presented here with the new ahpC suppressor mutations show that the suppression is dependent on the functioning of the glutathione/glutaredoxin pathway, but not the thioredoxin pathway. Furthermore, results presented here and elsewhere (Masip et al., 2006) show that the ahpC* suppressor mutation restores high levels of reduced glutathione to the trxB gor strain, whereas in the unsuppressed strain the absence of glutathione reductase prevents reduction of oxidized glutathione. With purified AhpC* protein we have sought to identify a substrate that would explain the restoration of reduced glutathione. AhpC* does not appear to reduce glutathione directly, because it shows only slight reductive activity toward oxidized glutathione that is only modestly higher than that of wild-type AhpC. Instead, the highest rate of GSH production was observed when glutathionylated glutaredoxins were used as substrates with AhpC* and all of the other mutant AhpCs tested in vitro. Thus, the ability of the ahpC suppressor mutations to restore growth to the trxB gor strains can be explained by the regeneration of reduced glutaredoxin, which is then able to reduce the essential enzyme ribonucleotide reductase (and presumably other protein disulfide bonds).
How do the various ahpC mutations shift the activity of AhpC from one that uses C46 for attacking substrates to one that uses C165? Our experiments show that, even in the absence of the AhpC* insertion or other mutations, wild-type AhpC does exhibit a low level of Grx-S-SG reductase activity. It seems most probable that the amino acid changes in the AhpC suppressor mutants increase this activity by conferring enhanced functioning of C165 toward glutathionylated substrates and/or by promoting the release of reduced products through AhpF-mediated reduction of the intermediate(s) formed. The simplest and most straightforward interpretation of our results emanates from the location of the suppressor mutations ( Figure 4A ), their effects on oligomerization and peroxidase activities, and our knowledge to date about at least two distinct conformations of bacterial AhpC that exist (PDB structures 1yep and 1n8j). In the fully folded form of AhpC, the C46 thiol is poised for catalysis within the active-site pocket and the C165 in the opposing subunit is buried within a different part of the structure (Wood et al., 2003; Parsonage et al., 2005) (Figure 4B ). The ''locally unfolded'' form of AhpC is represented by the disulfide-bonded structure 1yep, in which the C46 and C165 are flipped around with respect to the fully folded structure and have ''captured'' this conformation by intersubunit disulfide bond formation between them (Wood et al., 2002) (Figure 4C ). With this structural transformation, C165 moves to a more exposed position that, in the disulfide-bonded protein, allows it to act as the point of attack for reduction by AhpF (Hofmann et al., 2002; Wood et al., 2002; Jö nsson et al., 2007) . The extent to which the C165 thiol is more exposed in structures of the reduced AhpC suppressor mutants may therefore be a major determinant of the level of Grx-S-SG reductase activity exhibited by these proteins.
Other interconnected characteristics of less well-folded AhpC mutants also support this interpretation. In mutants at Thr77 designed to destabilize the dimer-dimer interface of AhpC decamers, the accompanying destabilizing effect of the loss of this oligomerization interface on the active site (and presumably the destabilization of the C-terminal region containing C165, as well) was associated with a large increase in K m for hydrogen peroxide (Parsonage et al., 2005) . Similarly, strong suppressor mutations studied here were generally associated with decamer destabilization and an accompanying high K m for peroxide (in cases where the mutants were active as peroxidases). In this regard, AhpC* is an extreme example of these characteristics, being completely dissociated into dimers and without peroxidase activity. Although there is as yet no real quantitative way to assess biological ''suppressor'' activity, the weakest suppressor, C46S AhpC, also appears to be the strongest decamer (L.B.P., unpublished data). As our decamer-weakening mutants at Thr77 described above (T77I and T77D) had the potential to act as suppressor mutants, we tested them for their ability to suppress the growth defect of trxB gor. We did not observe suppression, suggesting that, in spite of their ability to accumulate dimeric AhpC, these mutants lack structural features also needed to activate C165 for disulfide bond reduction. Thus, destabilization of the decamer may be either a functionally important feature of suppressor mutations or a more coincidental effect accompanying many of the mutations that enhance Grx-S-SG reductase activity in AhpC mutants.
Regarding the way in which the various mutations might work to impart this new activity to C165 through such structural effects, we can first consider the mutations, known to result in enhanced Grx-S-SG reductase activity, which lie close to C165, A167T, P161S, P166L, and S159P ( Figure 4A ). It is notable that three of the four involve changes that either substitute a proline residue for another residue or replace a proline residue. These alterations are likely to increase deglutathionylation activity by affecting the conformation of this region of the protein directly, resulting in greater exposure of C165 for catalysis.
Mutations that are proximal to the active-site C46 rather than C165 may also influence reactivity of the latter by destabilizing Shown are three views of AhpC dimers (partner subunits in light blue and green). The ''fully folded'' structure of the C46S mutant (PDB 1n8j, [A] and [B] ) is of an inactive version of the protein; based on other studies of related Prxs, this mutant protein apparently adopts the same conformation as does the reduced, wild-type version (Wood et al., 2003) . (C) depicts the ''locally unfolded'' structure of the disulfide-bonded, wild-type protein (PDB code 1yep). In this latter structure, the two cysteine residues participate in major structural rearrangements that allow formation of the disulfide bond and move C165 to a more exposed location on the surface of the protein; note that the electron density for about 20 residues at the C terminus of this protein (after C165) is missing and therefore in a disordered part of the structure. Though depicted as dimers, each of these proteins crystallized as decamers (Wood et al., 2002; Wood et al., 2003) . This figure was created using PyMOL v0.98 (DeLano Scientific LLC). the fully folded active site and C-terminal tail relative to wild-type AhpC, leading to greater exposure of the C165 thiol. As described above, the original mutant discovered to exhibit suppressor activity, AhpC*, is clearly disrupted in structure around the active site to the point that no peroxidatic activity is observed and the mutation completely disrupts decamer formation. In this case, the additional phenylalanine would effectively remove the OH group of Tyr38 that normally hydrogen bonds to a carboxylate oxygen of Asp41, displacing that Tyr from the edge of the b sheet into the loop that leads up to the peroxidatic C46. Like the AhpC* insertion, the other suppressor mutations that lie at or near the peroxidatic site, C46S, C46Y, C46F, G141S, and R119C (Figure 4A) , are also likely to cause structural perturbations around the active site that are transmitted across subunits to enhance the Grx-S-SG reductase activity of C165 in the adjacent subunit of the dimer. Such a mechanism that invokes the transmission between subunits of structural changes is supported by the striking finding that when AhpC* lacking C165, required for its activity, is expressed in cells also expressing wild-type AhpC, the enhanced disulfide reductase activity (suppression of the trxB gor growth defect) is observed. This occurs even though neither the cysteine-deficient AhpC* nor the wild-type AhpC themselves exhibit this activity. This result indicates that hetero-oligomers of AhpC*C165S and wild-type AhpC are formed and are active as disulfide reductases and that the former may alter the conformation of the latter so that the C165 of the wild-type monomer can act as a disulfide reductase.
Is the level of Grx-S-SG reductase activity sufficient to account for the suppressor phenotype? Whether the modest level of activity observed using the in vitro Grx1 C14S assay represents a sufficiently robust activity of AhpC* and the other mutants to support growth of E. coli can be partially addressed by calculations of the need to support DNA synthesis by ribonucleotide reductase. Ribonucleotide reductase may be the major essential protein requiring the activity of these reductive pathways. Based on the 4.6 Mb genome of E. coli, synthesis of both strands of the genome, and the ultimate need for the oxidation of two reduced glutathione molecules per deoxyribonucleotide synthesized, there would be a requirement for 1.84 3 10 7 GSH/cell per doubling, which occurs every $30 min for E. coli. From the calculation described in the Experimental Procedures, the expected release of reduced glutathione would be $2.6 3 10 7 per cell per 30 min for AhpC*, in an appropriate range to support the growth requirement. The activity of an equivalent amount of AhpC would produce about one-sixth that much GSH, an amount that would not reach the requirement for supporting RNR activity during normal growth but presumably would be expected to support a slower growth rate if this were the only factor. Of course, there may be additional needs for reduction of disulfide bonds within the cell, in which case the requirement for GSH would be higher than that needed just to support deoxyribonucleotide synthesis. Furthermore, expression levels of AhpC* or AhpC would modulate GSH production, as would any cellular effects on activity that are not well mimicked in our in vitro studies. Nonetheless, these calculations provide a framework for thinking about the levels of these measured activities relative to the needs of the cell. In considering actual in vivo substrates for AhpC* and the other mutant proteins, the Grx-S-SG reductase activity revealed by our experiments may also be associated with deglutathionylating activity toward other proteins that become glutathionylated under oxidizing conditions. At least three other E. coli proteins, OxyR, PAPS reductase, and MetE, the enzyme that catalyzes the final step of methionine biosynthesis, have been demonstrated to be glutathionylated under various conditions (Masip et al., 2006) . Although deglutathionylating activity toward a range of other substrates may play a role in the suppression of the growth defect in trxB gor mutants as well, the fact that our measured activity matches the biologically determined need for both Grx1 and glutathione in the suppression by these mutants suggests that Grx-S-SG reduction is the key activity the gives rise to the biological effects of these mutants. The enhancement of total glutathione levels as observed in AhpC* expressing cells may also contribute to some extent to the rescue of these mutants, although this issue requires further exploration. Modulation of glutathione levels is apparently not a requirement for the suppressor activity, however, as four of the mutants tested had reduced and oxidized glutathione levels essentially indistinguishable from those of the parental wild-type strain DHB4 (see Figure S3) .
Finally, we have previously proposed that the triplet repeat expansion seen in the ahpC* mutation, which appears at high frequency in the trxB gor background, may provide an evolutionary advantage for E. coli (Ritz et al., 2001) . The ability to switch genetically from utilizing NADPH (thioredoxin reductase and glutathione reductase) to NADH (AhpC* disulfide reductase) may allow a fraction of the bacteria to respond to conditions where NADPH is depleted from cells (Liochev and Fridovich, 1992; Derman and Beckwith, 1995) and to conditions of disulfide stress (Å slund and Beckwith, 1999) . However, analogous triplet repeats in ahpC are found in few other bacteria. We have considered the possibility that other bacteria might have evolved similar compensatory mechanisms by employing point mutations of the type we have described in this paper. Thus, using a bioinformatic analysis, we have asked whether other organisms may contain such disulfide reductase-imparting ahpC mutations as possible evolved versions of the protein, using BLAST (http://www.ncbi.nlm.nih. gov/BLAST/) to scan the collection of sequenced bacterial genomes for AhpC homologs. We have found a number of bacteria that have more than one AhpC homolog. In these cases, some of the AhpC copies have retained all of the conserved amino acids in the region of C165, whereas an additional, more divergent AhpC homolog in the same organism contains alterations in some of the same amino acids that we have identified here as sites of suppressor mutations (see Table S2 for details). These organisms may switch to alternative mechanisms of disulfide reduction utilizing the alternative versions of AhpC by a regulatory switch rather than a genetic switch. Future studies will examine these latter proteins to determine whether they have acquired similar properties to the altered AhpC proteins presented in this work.
Regarding the broad implications of our studies, it has been recognized for quite some time that the molecular evolution of new functions can proceed by co-opting existing scaffolds and chemical features to elaborate new and distinctive functional attributes. Studies rarely provide the opportunity, however, to catch this process ''in the act.'' With our new findings reported here, it is clear that we have a case where single amino acid insertions or substitutions do indeed impart a new function (Grx-S-SG reductase activity) using a newly modulated active site (centered around C165) that is completely independent of the key residue that functions in the peroxidase activity (C46). Moreover, the Grx-S-SG activity may be enhanced or repressed by the same sort of dynamic and structural features around the active site and resolving cysteine residues that are increasingly recognized to influence such other functional features as catalytic efficiency and susceptibility toward substrate-mediated inactivation (Koo et al., 2002; Wood et al., 2003; Parsonage et al., 2005) . With further experimentation, we hope to address the broader significance of this new activity for wild-type AhpC's and other peroxiredoxins in biology.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Plasmids, Growth Conditions, and Protein Preparation All strains used in this work are derivatives of strain DHB4; strains and plasmids used in this study are listed in the Supplemental Data, Table S1 . Growth conditions and methods for expressing and purifying proteins used in these studies are also described in the Supplemental Data.
Screening for ahpC Mutants Capable of Reducing Disulfide Bonds
Mutagenesis with E. coli XL1-Red (Stratagene, Cedar Creek, TX) was done as described by the manufacturer. Briefly, in two independent rounds of mutagenesis, pJL34 was transformed into XL1-Red cells and plated on NZY-Cm plates. Colonies were then scratched from the plate and a plasmid pool was isolated from the cells and retransformed into DR456 lacking the chromosomal ahpCF copy to eliminate the possibility of picking up the growth-restoring high frequency triplet repeat expansions. Plasmids from strains growing on NZ-Cm plates in the presence of 0.2% glucose were isolated and reintroduced into DR456 to confirm that a mutation in ahpCF was responsible for the growth phenotype. Sequencing of mutant ahpC plasmids revealed seven different mutations, which we then characterized.
The mutations of several selected ahpC variants were constructed in the expression plasmid pTrc99a_ahp by using the QuikChange approach. The three remaining mutations that were not incorporated into the pTrc99a plasmid were ones that resulted in the changes C46Y, R119C, and G141S.
Selection of New Mutants In Vivo in a katG Background
The katG::Tn10 allele from HP27 was introduced via generalized P1 transduction into an arabinose-dependent trxB gor double mutant derived from JL10 in which gor had been disrupted by a kanamycin resistance marker. The resulting strain (DR599) was dependent on the presence of arabinose for the expression of the thioredoxin reductase. A spontaneous mutant (DR600) that restored growth was obtained on glucose plates and could be transferred by cotransduction with a Tn10Cm marker linked to the ahpC locus. DR600 contained an ahpC mutation resulting in P166L (C500T).
OxyR Activation Assessed by b-Galactosidase Activity b-galactosidase assays in strains derived from HP27 were performed as described (Miller, 1972) . As controls in the assays of P trxC -lacZ strains, we used a strain containing the wild-type ahpCF operon and the empty plasmid. Also, we assessed a plasmid expressing AhpC C46Y. Except for the latter, the assays were done in duplicate with errors of less than 2%. The percentages presented in Table 2 were calculated by defining as 100% peroxidase activity the low level of b-galactosidase activity of the wild-type ahpC plasmid-containing strain; 0% peroxidase activity was defined as the high b-galactosidase activity measured for the strain with the empty plasmid. The percentage of peroxidase activity as measured by OxyR activation for each mutant was then scaled appropriately.
Defining Redox Components Necessary for Suppression by Mutant AhpC
To test for which gene products of the thioredoxin or glutathione pathways were required to mediate the suppression by ahpC mutations, suppressed strains deleted for either trxA, grxA, or gshA were restreaked from dithiothreitol (DTT)-containing NZ-amine plates onto NZ-amine plates lacking reductant but containing 50-150 mM isopropyl b-D-thiogalactopyranoside (IPTG). Plates were incubated overnight at 37 C, and growth, as indicated by ability to form colonies, and colony size, as compared to control strains, were observed the following day. The ability of ahpC mutants to suppress growth defects was tested in SMG67 strain on NZ plates in the presence of glucose and 0.1 mM IPTG.
Peroxidase Assay
Peroxidase activity of AhpC mutants was measured by monitoring the loss of fluorescence from the S128W mutant of the separately expressed AhpF N-terminal domain (NTD S128W) as it was oxidized in the presence of AhpC and hydrogen peroxide. The ranges of protein and hydrogen peroxide used for this assay were from 0.05 to 0.30 mM for AhpC, from 1.25 to 20 mM for NTD S128W, and from 0.5 to 8000 mM for hydrogen peroxide. Enzyme assays and calculation of K m , k cat , and k cat /K m values were done as described previously (Parsonage et al., 2005) .
Measurement of Reduced and Oxidized Glutathione
Content in E. coli Cells An exponential culture of 20 ml of E. coli was centrifuged at 5000 3 g for 5 min, and the cells were suspended in 200 ml of 5% metaphosphoric acid (Sigma). Glutathione was extracted by incubating the cell suspension on ice for 30 min. After the cell debris and proteins were precipitated by centrifugation at 11,000 3 g for 15 min, the supernatant was used for glutathione measurement. The amount of both oxidized and reduced glutathione in each sample was determined by using a glutathione quantification kit (BIOXYTECH GSH/ GSSG-412, OxisResearch) per the supplier's instructions. Glutathione content in the cell was calculated by dividing the total amount of glutathione in 20 ml of cell culture by the total protein content in that same amount of culture; protein concentration was measured by the BCA assay (Pierce).
Monitoring AhpC-Dependent, Reduced Glutathione Formation In Vitro The basal reaction mixture contained 50 mM potassium phosphate (pH 7.0), 0.1 M ammonium sulfate, 1 mM EDTA, and 1 mM GSSG. One-hundred units per milliliter bovine catalase (Sigma) was also included in the reaction mixture to prevent accumulation of hydrogen peroxide derived from the hydrogen peroxide-forming NADH oxidase activity of AhpF. To the basal reaction mixture was added 0.5 mM of AhpF, 10 mM Grx (Grx1, Grx1 C14S, or Grx4), and/or 5 mM AhpC (including wild-type AhpC, AhpC*, AhpC*C46S, AhpC*C165S, S159P, P161S, A167T, or P166L). The reaction was started by adding NADH to the reaction mixture to a final concentration of 0.8 mM. After incubation at 22 C for an appropriate time period, an aliquot of the reaction mixture was mixed with one-tenth volume of 50% metaphosphoric acid solution and incubated on ice for 30 min. Proteins in the reaction mixture were precipitated by centrifugation at 11,000 3 g for 15 min. Reduced glutathione in the supernatant was then quantified with DTNB. The supernatant was mixed with an equal volume of 2 M Tris-HCl (pH 8.0) containing 200 mM DTNB. After 10 min incubation at room temperature, 2-nitro-5-thiobenzoate (TNB) formation in the mixture was quantified by measuring A 412 . Assays monitoring the reduction of stably formed conjugates between glutathione and Grx proteins with MALDI-TOF were conducted as described in the Supplemental Data.
Estimation of Cellular GSH Formed by AhpC* The whole protein profile of FA113, an original isolate of the suppressor for trxB gor, and of MJF306 was analyzed by SDS-PAGE. The amount of AhpC* present in each strain was estimated by scanning of the gel and processing of the image with Image J software (http://rsb.info.nih.gov/ij/) using three concentrations of purified AhpC* as a standard. The amount of AhpC* expressed in both FA113 and MJF306 (with 0.1 mM IPTG) was high, at $2% of total protein. The total protein amount per E. coli cell was determined by measuring the total protein amount and colony-forming units of an exponential phase culture of MJF306 (with 0.1 mM IPTG). The obtained value of total protein amount per E. coli cell (5.1 3 10 À13 g) allowed us to estimate the number of AhpC* subunits per cell to be around 3.0 3 10 5 . The in vitro assay described above showed that each subunit of AhpC* generates 88 GSH per 30 min at 37 C (wild-type AhpC generates 14 GSH per 30 min). Accordingly, the number of GSH molecules that can be generated by AhpC* was calculated to be $2.6 3 10 7 GSH/ cell/30 min.
Supplemental Data
Supplemental Data include Supplemental Results, Supplemental Experimental Procedures, four figures, and two tables and can be found with this article online at http://www.molecule.org/cgi/content/full/29/1/36/DC1/.
